We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
The current BCLI market cap is 9.64M. The company's latest EPS is USD and P/E is N/A.
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.59M | -6.84M | -4.92M | -5.15M | -5.45M |
| Net Income | -7.04M | -6.86M | -5.02M | -5.06M | -5.33M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.06M | -23M | -31.68M | -24.54M | -24.82M |
| Net Income | -13.95M | -23.25M | -31.81M | -24.46M | -24.28M |
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 18.96M | 13.25M | 8.45M | 7.87M | 5.75M |
| Total Liabilities | 11.11M | 11.87M | 11.47M | 12.71M | 9.63M |
| Total Equity | 7.85M | 1.39M | -3.02M | -4.84M | -3.88M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 11.23M | 6.53M | 51.26M | 29.28M | 8.45M |
| Total Liabilities | 6.21M | 18.76M | 15.8M | 9.94M | 11.47M |
| Total Equity | 5.02M | -12.22M | 35.46M | 19.34M | -3.02M |
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -9.82M | -14.67M | -19.32M | -3.99M | -10.76M |
| Investing | -29k | -40k | 998k | 2.01M | 2.01M |
| Financing | N/A | N/A | 238k | 3.23M | 8.53M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -12.39M | -11.25M | -35.19M | -26.27M | -19.32M |
| Investing | -1.22M | 5.62M | -4.45M | 323k | 998k |
| Financing | 12.07M | 5.23M | 76.94M | 6.97M | 238k |
| Market Cap | 9.64M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 48.98M |
| Average Volume (1 week) | 8.15M |
| Average Volume (1 Month) | 4.6M |
| 52 Week Change | -86.97% |
| 52 Week High | 3.46 |
| 52 Week Low | 0.134 |
| Spread (Intraday) | 0.01 (4.83%) |
| Company Name | Brainstorm Cell Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.brainstorm-cell.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: 1-888-992-3836 | help@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
